Nicole Askin

Jul 22, 2024 | annfammed.org | George N. Okoli |Nicole Askin |Rasheda Rabbani |Max Rady College

AbstractBACKGROUND The efficacy, effectiveness, and safety of the approved nirmatrelvir/ritonavir regimen for treatment of laboratory-confirmed mild/moderately severe COVID-19 remains unclear. METHODS We systematically identified randomized controlled trials (RCTs) and real-world studies (RWS; observational studies) of the efficacy/effectiveness and/or safety of the approved nirmatrelvir/ritonavir regimen for COVID-19.

Jul 1, 2024 | rb.gy | George N. Okoli |Nicole Askin |Rasheda Rabbani |Max Rady College

Key words:nirmatrelvir/ritonavirPaxlovidlaboratory-confirmed COVID-19systematic reviewquantitative methods: meta-analysistrial sequential analysisefficacy/effectivenesssafetyINTRODUCTIONThe virus responsible for the COVID-19 pandemic, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), remains in circulation.